Novo Nordisk manufactures and markets pharmaceutical products and services. Key products include diabetes care medications and devices. Novo Nordisk is also involved with hemostasis management, growth hormone therapy and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, NovoLog, Novolin R, NovoSeven, NovoEight and Victoza. In India, Novo Nordisk has two centers – Novo Nordisk India and Novo Nordisk Service Centre India. Novo Nordisk India provides patient care solutions – products and services and Novo Nordisk Service Centre India is the internal offshoring hub of Novo Nordisk globally. Novo Nordisk employs approximately 41,500 employees in 75 countries, and markets its products in more than 180 countries.
Today’s research and development environment is becoming increasingly data intensive. Reaping full benefits of the revolution in data generation will require translating big data to knowledge in basic research and applications. This meeting will bring together world leading researchers in using data and computational models to address challenges in translational biotechnology applications. The meeting will cover 1) development of concepts and methods to deal with the big data challenge, 2) applications of data-driven strategies in industrial biotechnology, and 3) uses of models and data in human health-related biotechnology. Specific topics covered include genome-scale models, new omics technologies, cellular metabolism and its regulation, engineering of microbial and mammalian cell factories, microbial pathogens and communities, and omics data and models in human disease. The meeting is targeted towards anyone interested in interdisciplinary bioscience research and in particular uses of data to advance biotechnology applications.
Projects involve a clear element of biotechnology, and may in addition utilize any other scientific and engineering discipline relevant to achieve the objectives. Projects should include one or more of the following topics:
- Use or engineering of biological tools and systems for synthesis and production of valuable products (for example, chemicals, fuels, bioactive compounds, proteins, materials as well as fibre, food and feed products).
- Development of technologies and processes that can directly support biotechnology-based synthesis and production.
- Improvement of the production potential of microorganisms, plants, animals, or enzymes.
- Biotechnology to improve raw material utilization, reduce energy consumption and/or decrease waste generation.
- Projects must contain a laboratory component and show a clear and plausible path from the proposed research to applications in the area of biotechnology-based synthesis and production.
As novo nordisk is a healthcare company with lot of projects being going on diabetes and are research related thus a need for biotech professional becomes a need for these healthcare centre to hire biotechnological professionals in these companies or a person with biological background becomes a criteria. Novo Nordisk joins Alnylam and GlaxoSmithKline on the list of drugmakers to make notable investments in the U.K. since the vote to leave the EU. The £115 million commitment will support the creation of the Novo Nordisk Research Centre Oxford at the university’s biomedical campus in Headington and its first 10 years of operation.
Over that time, Novo Nordisk hopes its researchers will work with their neighbors at the university to discover new targets and other early-stage advances with the potential to improve treatment of Type 2 diabetes and its complications. To facilitate such cooperation, Novo Nordisk will provide funding for collaborative research that bridges the industry-academia divide.